Phase 2 MMY2002 trial of daratumumab in patients with at least 3 lines of prior therapy or double refractory multiple myeloma | Dr María-Victoria Mateos at Annual Meeting 2015

Phase 2 MMY2002 trial of daratumumab in patients with at least 3 lines of prior therapy or double refractory multiple myeloma | Dr María-Victoria Mateos at Annual Meeting 2015

EMJ

4 years
1,025 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, María-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, discusses the results of the phase 2 MMY2002 trial of the anti-CD38 monoclonal antibody, daratumumab, in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Who is Eligible for the AVIATOR Study? @SeattleCCA
Who is Eligible for the AVIATOR Study? @SeattleCCA
Category: Breast Cancer
1 Views
SeattleCCA 1 hour
The AVIATOR Study @SeattleCCA
The AVIATOR Study @SeattleCCA
Category: Breast Cancer
0 Views
SeattleCCA 2 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Impacting HCC Outcomes with Multimodal Therapy: The Importance of Interdisciplinary Management
Category: Liver Cancer
0 Views
imedex 4 hours